A Second View: Discussing Welireg (Belzutifan) as a treatment in patients with von Hippel-Lindau (VHL) disease with associated renal cell carcinoma

Executed on:Mar 23, 2022 4:30 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Huntsman Cancer Institute, University of Utah

Assistant Professor in the Division of Medical Oncology at Huntsman Cancer Institute specializing in genitourinary malignancies
Participated in two clinical trials with Welireg and is now using it as standard of care
Clinical and research interests in all genitourinary oncology, with a particular focus on the development of novel therapeutics and in identification of predictive biomarkers.

Interview Goal

To discuss the use and potential of Welireg(Belzutifan) as a treatment in patients with von Hippel-Lindau (VHL) disease with associated renal cell carcinoma.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.